Vivoryon Therapeutics N.V. (AMS:VVY)
Netherlands · Delayed Price · Currency is EUR 1.110
0.00 (0.00%)
Sep 25, 2026, 5:35 PM CET
Vivoryon Therapeutics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -6.77 | -8.85 | -20.57 | -28.34 | -28.16 | -12.66 |
Depreciation & Amortization | 0.14 | 0.15 | 0.15 | 0.17 | 0.16 | 0.17 |
Loss (Gain) From Sale of Investments | - | - | - | - | 0.01 | 0.08 |
Stock-Based Compensation | 0.38 | 0.89 | 2.18 | 3.94 | 3.49 | 1.76 |
Provision & Write-off of Bad Debts | - | - | - | -0.04 | -0.05 | 0.1 |
Other Operating Activities | 0.07 | 0.1 | 0.77 | 2.97 | 1.73 | -0.13 |
Change in Accounts Payable | -0.63 | -0.55 | -1.9 | 0.54 | -1.72 | 3.45 |
Change in Other Net Operating Assets | -0.29 | -0.19 | 0.2 | -0.77 | 2.76 | -4.03 |
Operating Cash Flow | -7.1 | -8.46 | -19.17 | -21.54 | -21.79 | -11.26 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0 | -0.01 | -0 | -0.01 | -0.01 | -0.02 |
Sale (Purchase) of Intangibles | - | - | - | -0.5 | -0 | -0.01 |
Investment in Securities | - | - | 10 | -10 | - | - |
Investing Cash Flow | 0 | -0.01 | 10 | -10.51 | -0.01 | -0.03 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.06 | -0.06 | -0.09 | -0.09 | -0.09 |
Lease Payments | -0.06 | -0.06 | -0.06 | -0.09 | -0.09 | -0.09 |
Net Debt Issued (Repaid) | -0.06 | -0.06 | -0.06 | -0.09 | -0.09 | -0.09 |
Issuance of Common Stock | 5.07 | 5.07 | - | 26.35 | 36 | 1.14 |
Other Financing Activities | -0.3 | -0.3 | - | -2.1 | -2.53 | -1.88 |
Financing Cash Flow | 4.71 | 4.72 | -0.06 | 24.16 | 33.38 | -0.83 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | - | - | 0.04 | -0.1 | 0.32 | 0.47 |
Net Cash Flow | -2.39 | -3.75 | -9.2 | -7.99 | 11.89 | -11.65 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.11 | -8.46 | -19.18 | -21.56 | -21.81 | -11.28 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | - | - | - | - | -104.77% |
Free Cash Flow Per Share | -0.25 | -0.31 | -0.74 | -0.85 | -0.99 | -0.56 |
Levered Free Cash Flow | -3.76 | -4.34 | -9.91 | -11.59 | -14.93 | -5.47 |
Unlevered Free Cash Flow | -3.73 | -4.32 | -9.88 | -11.55 | -14.91 | -5.46 |
Free Cash Flow After Leases | -7.17 | -8.52 | -19.23 | -21.65 | -21.9 | -11.37 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0 | 0 | 0 | 0 | 0 | 0.01 |
Change in Working Capital | -0.93 | -0.74 | -1.7 | -0.24 | 1.03 | -0.58 |